Related Experiment Videos
ACE-inhibitor therapy after myocardial infarction--a new treatment strategy
Abstract:
Potential benefit or harm of drug therapy in patients with chronic congestive heart failure and those later presenting to hospital after an acute myocardial infarction (AMI) have been studied in a number of large-scale survival studies during the last few decades. Currently available data are reviewed in order to consider both methodology and also the clinical relevance of findings with emphasis on trials with ACE-inhibitors like CONSENSUS-II, the ISIS-4, GISSI-3 and Chinese mega-trials, TRACE, SAVE and AIRE. Results of SAVE and AIRE show a clear survival benefit for the patients. Furthermore, the benefit of both trials was in addition to any other benefit which resulted from aspirin, thrombolytic and beta-blocker therapies. In absolute terms, treatment of 1,000 patients with ramipril (AIRE) for 1 year would be expected to result in the prevention/delay of 40 premature deaths. The beneficial effects of ramipril were clearly apparent by 30 days though additional benefit beyond this point was also present. Furthermore, prespecified subgroup analysis revealed significant benefit for patients at risk like women and the elderly. A selective approach is argued for the treatment of patients with ACE-inhibitors after myocardial infarction.
Insights
Angiotensin-converting enzyme (ACE) inhibitors demonstrate survival benefits in patients post-acute myocardial infarction (AMI). Ramipril treatment, for instance, significantly reduces premature deaths, especially in high-risk groups like women and the elderly.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Large-scale survival studies have investigated drug therapies for chronic congestive heart failure and acute myocardial infarction (AMI).
- Previous research has focused on the potential benefits and harms of various drug classes.
Purpose of the Study:
- To review current data on drug therapy for patients with chronic congestive heart failure and post-AMI.
- To evaluate the methodology and clinical relevance of findings from major clinical trials, particularly those involving ACE inhibitors.
Main Methods:
- Review of data from large-scale survival studies, including CONSENSUS-II, ISIS-4, GISSI-3, TRACE, SAVE, and AIRE.
- Emphasis on trials investigating ACE inhibitors (e.g., ramipril).
Main Results:
- The SAVE and AIRE trials demonstrated a clear survival benefit for patients treated with ACE inhibitors.
- This benefit was observed in addition to therapies like aspirin, thrombolytics, and beta-blockers.
- Ramipril treatment (AIRE trial) showed an absolute reduction of 40 premature deaths per 1,000 patients treated for 1 year, with benefits evident by 30 days.
- Subgroup analyses indicated significant benefits for high-risk patients, including women and the elderly.
Conclusions:
- ACE inhibitors, such as ramipril, offer significant survival advantages for patients following an acute myocardial infarction.
- A selective approach to prescribing ACE inhibitors post-MI is recommended, considering patient-specific risk factors.